welgenaleucel (UWC19) / UWELL Biopharma - LARVOL DELTA

Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov) - P1; N=20; Recruiting; Sponsor: UWELL Biopharma; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Pre-clinical assessment of chimeric antigen receptor t cell therapy targeting CD19+ B cell malignancy. (PubMed, Ann Transl Med) - "We developed a novel CAR against CD19 namely UWC19, consisting anti-CD19 single-chain variable fragment (scFv) hinged with 4-1BB and CD3z signaling domains...The findings suggest encouraging clinical prospects for its use in patients with CD19 positive B cell malignancies. Our study presented an alternative evaluation strategy for CAR-T cell products."

CAR T-Cell Therapy • Journal • Graft versus Host Disease • Hematological Malignancies • Immunology • Oncology

Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov) - P1; N=20; Not yet recruiting; Sponsor: UWELL Biopharma

Clinical • New P1 trial